Facts and myths about overdose and take-home naloxone — EMCDDA publishes new resources
Over the past five years, more than 40 000 people have died of a drug-related overdose in the European Union and the UK; around 80% of these being linked to the use of heroin or other opioids. Yet, with effective intervention, they could have been prevented.
World Hepatitis Day: EMCDDA showcases hepatitis questionnaire for drug service staff to refresh knowledge and identify training needs
Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day to increase awareness and understanding of viral hepatitis and the diseases it causes.
Stronger together: EU agencies join forces to respond to COVID-19
Since the start of the COVID-19 pandemic, the nine JHA agencies (CEPOL, EASO, EIGE, EMCDDA, eu-LISA, Eurojust, Europol, FRA and Frontex) have been supporting the EU Member States and institutions in meeting the unprecedented challenges resulting from the outbreak of the virus in both the short an
EMCDDA welcomes external partners to virtual event on lessons learned from the impact of COVID-19 on the drug situation in Europe
The EMCDDA will be joined by a range of its external partners today in a virtual event following on from International day against drug abuse and illicit trafficking (26 June).
EMCDDA and Europol join EU institutions in dialogue on the impact of COVID-19 on the world drug situation
On the occasion of International day against drug abuse and illicit trafficking, the EMCDDA and Europol are joining representatives of the EU institutions today in providing the European perspective on the impact of COVID-19 on the world drug situation.
EMCDDA Management Board renews mandate of Alexis Goosdeel
The EMCDDA Management Board took the unanimous decision today to renew the mandate of the agency’s Director, Alexis Goosdeel, for the next five years. Mr Goosdeel took up the post of EMCDDA Director on 1 January 2016 and will now hold the position until 31 December 2025.
COVID-19: New EMCDDA study highlights decline in stimulant drug use but some rises in the use of cannabis, alcohol and prescription medicines to combat anxiety and depression
A decline in stimulant drug use but some rises in the consumption of cannabis and licit substances are among the findings presented today in a new EMCDDA report The impact of COVID-19 on patterns of drug use an
New Zealand: referendum on cannabis legalisation to take place in September 2020
Following an agreement made in 2017 between the ruling coalition parties in New Zealand, it has been announced that a referendum on legalising the recreational use of cannabis will be held together with the next general election, on 19 September 2020.
Increase in darknet market activity for cannabis as users stock up for lockdown
The COVID-19 pandemic has profoundly impacted on our daily lives, including our behaviour as consumers. Just as we have seen online shopping for other goods increase during lockdowns, will we see a similar shift when it comes to illicit drugs?
EMCDDA launches COVID-19 special round of European Web Survey on Drugs to assess impact of pandemic
Crucial information on the impact of COVID-19 on people who use drugs, and on the services that support them, will be collected via a special round of the European Web Survey on Drugs, launched this week.
25 years of monitoring — selected events from the EMCDDA’s international cooperation history
Drugs have long been a cross-border phenomenon. As drug problems in Europe are increasingly linked to, and influenced by, global developments, it is crucial that our analysis of trends and developments be placed in the wider international context.